The following is a summary of “Patient journey and decision processes for anti-amyloid therapy in Alzheimer’s disease,” ...

This study included 97 patients (57 had cardiac transthyretin amyloidosis, 20 had cardiac light chain amyloidosis, 3 had ApoA1 or ApoA4, 8 had systemic amyloidosis but no cardiac involvement, and 17 ...

RIKEN researchers have demonstrated the protective effects of a specific genetic mutation against Alzheimer's disease in ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

Space, An Early Frontier. When a brain region is tau-negative by SUVR (green arrow, left), spatial extent (dark blue) correlates better with measures of disease severity than does SUVR (light blue).

The deal gives the Anglo-Swedish drugmaker complete control of Caelum's late-stage medicine for light chain (AL) amyloidosis, a potentially fatal disease that causes the rogue protein amyloid to ...

A novel artificial intelligence (AI) tool has revealed how disease-linked proteins misfold into harmful structures, a key ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

It binds both transmembrane and soluble TREM2, triggering a rise in CSF sTREM2. Single and multi-dose studies of the small ...

COGNITIVE phenotyping significantly enhances the accuracy of blood phosphorylated tau 217 (p-tau217) in predicting brain ...